Table I.
Equivalence Value Determined from Different Analysis Methods and the Working Group Evaluation
| Scenario | UV-Abs | Par-Abs | UV-Nor | Par-Nor | Chi-2 + ISM | WG |
|---|---|---|---|---|---|---|
| 1a | 0.64 | 0.73 | 0.68 | 0.77 | 0.70 | 1.00 |
| 1b | 0.53 | 0.62 | 0.60 | 0.65 | 0.22 | 0.79 |
| 1c | 0.34 | 0.46 | 0.42 | 0.47 | 0.01 | 0.07 |
| 1d | 0.20 | 0.28 | 0.20 | 0.26 | 0.00 | 0.00 |
| 1aa | 0.76 | 0.86 | 0.79 | 0.87 | 0.81 | 1.00 |
| 1bb | 0.55 | 0.61 | 0.56 | 0.60 | 0.48 | 0.79 |
| 1cc | 0.39 | 0.51 | 0.47 | 0.51 | 0.01 | 0.36 |
| 1dd | 0.20 | 0.29 | 0.25 | 0.28 | 0.00 | 0.00 |
| 1ee | 0.18 | 0.25 | 0.20 | 0.22 | 0.00 | 0.00 |
| 2a | 0.67 | 0.74 | 0.68 | 0.78 | 0.89 | 0.79 |
| 2b | 0.45 | 0.51 | 0.46 | 0.53 | 0.92 | 0.50 |
| 2c | 0.43 | 0.46 | 0.44 | 0.47 | 0.89 | 0.21 |
| 2aa1 | 0.66 | 0.70 | 0.67 | 0.70 | 0.88 | 0.71 |
| 2bb1 | 0.47 | 0.51 | 0.49 | 0.60 | 0.80 | 0.64 |
| 2cc1 | 0.48 | 0.57 | 0.54 | 0.60 | 0.74 | 0.50 |
| 2dd1 | 0.46 | 0.55 | 0.48 | 0.54 | 0.89 | 0.29 |
| 2aa2 | 0.49 | 0.52 | 0.49 | 0.53 | 0.90 | 0.64 |
| 2bb2 | 0.48 | 0.51 | 0.49 | 0.52 | 0.89 | 0.29 |
| 2cc2 | 0.41 | 0.41 | 0.42 | 0.43 | 0.94 | 0.14 |
| 4a | 0.90 | 0.93 | 0.91 | 0.94 | 0.88 | 1.00 |
| 4b | 0.07 | 0.51 | 0.19 | 0.51 | 0.89 | 1.00 |
| 4c | 0.08 | 0.26 | 0.11 | 0.26 | 0.68 | 0.21 |
| 4d | 0.07 | 0.21 | 0.09 | 0.19 | 0.45 | 0.14 |
| 5a | 0.72 | 0.78 | 0.74 | 0.80 | 0.89 | 0.93 |
| 5b | 0.35 | 0.42 | 0.39 | 0.44 | 0.86 | 0.86 |
| 5c | 0.12 | 0.16 | 0.15 | 0.16 | 0.50 | 0.29 |
| 7a | 0.21 | 0.21 | 0.23 | 0.23 | 0.89 | 0.29 |
| 7b | 0.44 | 0.48 | 0.49 | 0.53 | 0.95 | 0.50 |
| 7c | 0.71 | 0.76 | 0.74 | 0.79 | 0.92 | 0.93 |
| 10a | 0.18 | 0.17 | 0.17 | 0.16 | 1.00 | 0.14 |
| 10b | 0.20 | 0.17 | 0.20 | 0.17 | 1.00 | 0.29 |
| 10c | 0.41 | 0.41 | 0.41 | 0.41 | 1.00 | 0.50 |
| 10d | 0.71 | 0.73 | 0.73 | 0.74 | 1.00 | 1.00 |
| 11a | 0.36 | 0.39 | 0.49 | 0.51 | 0.78 | 0.64 |
| 11b | 0.59 | 0.62 | 0.72 | 0.74 | 1.00 | 1.00 |
| 11c | 0.82 | 0.84 | 0.83 | 0.87 | 1.00 | 1.00 |
| 12a0 | 0.05 | 0.06 | 0.05 | 0.06 | 0.07 | 0.07 |
| 12a1 | 0.07 | 0.09 | 0.07 | 0.10 | 0.82 | 0.14 |
| 12a2 | 0.10 | 0.15 | 0.10 | 0.16 | 1.00 | 0.86 |
| 12a3 | 0.12 | 0.27 | 0.13 | 0.29 | 1.00 | 1.00 |
| 12b0 | 0.11 | 0.16 | 0.11 | 0.17 | 0.03 | 0.29 |
| 12b1 | 0.17 | 0.26 | 0.19 | 0.31 | 0.93 | 0.86 |
| 12b2 | 0.25 | 0.44 | 0.27 | 0.47 | 1.00 | 0.86 |
| 12b3 | 0.31 | 0.55 | 0.33 | 0.56 | 1.00 | 1.00 |
| 13a | 0.46 | 0.71 | 0.69 | 0.74 | 0.40 | 1.00 |
| 13b | 0.29 | 0.60 | 0.43 | 0.65 | 0.38 | 0.57 |
| 13c | 0.22 | 0.41 | 0.24 | 0.49 | 0.26 | 0.36 |
| 13d | 0.12 | 0.38 | 0.29 | 0.43 | 0.00 | 0.21 |
| 13e | 0.07 | 0.35 | 0.23 | 0.44 | 0.00 | 0.07 |
| 13f | 0.38 | 0.87 | 0.50 | 0.90 | 0.84 | 0.93 |
| 13g | 0.29 | 0.71 | 0.42 | 0.75 | 0.83 | 0.50 |
| 14a1 | 0.06 | 0.20 | 0.07 | 0.13 | 0.00 | 0.00 |
| 14a2 | 0.06 | 0.25 | 0.09 | 0.18 | 0.00 | 0.07 |
| 14a3 | 0.07 | 0.23 | 0.12 | 0.22 | 0.03 | 0.43 |
| 14a4 | 0.07 | 0.26 | 0.15 | 0.28 | 0.37 | 0.71 |
Column I: scenario ID. Columns II–V: equivalence (Eq value) determined based on orthogonal partial least square analysis with different data pretreatment methods. Eq values in columns II–V are the average of three individual simulations (n = 3, 5,000 each). Column VI: likelihood of equivalence based on the combination test proposed by the US FDA and the PQRI working group. Column VII: equivalence evaluated by the working group. The likelihood of equivalence from the working group evaluation and the combination test were retrieved from Ref. (14)
UV-Abs absolute mass data were pretreated with unit-variance scaling, Par-Abs absolute mass data were pretreated with Pareto scaling, UV-Nor normalized percent mass data were pretreated with unit-variance scaling, Par-Nor normalized percent mass data were pretreated with Pareto scaling, Chi-2 + ISM chi-square ratio statistics supplemented by a population bioequivalence test for impactor-sized mass, WG working group evaluation